Clinical Study

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study

Table 2


Baseline (IQD) 𝑛 = 3 0 After 8 weeks of treatment (IQD) 𝑛 = 2 8 Wilcoxon signed ranks Test

Median frequency/day11.7 (9.3–13.4)9.5 (6.9–10.9) 𝑃 = . 0 0 0
Median volume voided/void121.9 (103.1–152.9)155.3 (103.1–198.2) 𝑃 = . 0 0 0
Median incontinence episodes/day1.3 (0.0–2.7)0.2 (0.0–1.7) 𝑃 = . 3 6 0
Median no. pads used/day2.0 (0.0–3.4)1.0 (0.0–2.0) 𝑃 = . 0 1 0
Median severity of urine loss (0–3; daily added score)1.2 (0.0–5.0)0.3 (0.0–2.8) 𝑃 = . 0 5 3
Median degree of urgency prior to voiding (0–3; daily added score)36.3 (28.8–47.3)23.7 (18.0–31.0) 𝑃 = . 0 0 0